Literature DB >> 19280190

Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.

Maiko Suzuki1, Manabu Endo, Fumiaki Shinohara, Seishi Echigo, Hidemi Rikiishi.   

Abstract

PURPOSE: The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances cisplatin [cis-diammine dichloroplatinum (II)] (CDDP)-induced apoptosis in the oral squamous cell carcinoma (OSCC) cell line by complex, multifunctional mechanisms. We investigated the role of endoplasmic reticulum (ER) stress in the enhancing effect of SAHA on CDDP, compared with the ER stressor thapsigargin.
METHODS: We chose OSCC cell line HSC-3 to ascertain the mechanism of SAHA-enhanced cytotoxicity among various cell lines. HSC-3 cells were incubated with CDDP/SAHA for 48 h, followed by the assessment of cell chemosensitivity to CDDP with MTT and TUNEL assays. Western blot analysis was used to detect the expressions of ER-related molecules, and flow cytometry was used to monitor caspase activity.
RESULTS: Treatment with CDDP/SAHA potently induced apoptosis in HSC-3 cells with a significant increase in caspase-4 and -12 functions. For example, 60% of cells became apoptotic after 48 h of treatment with CDDP/SAHA. In addition, SAHA alone rapidly induced sustained phosphorylation of eukaryotic translation initiation factor-2 (eIF2)alpha, which is up-regulated during ER stress. Inhibition of ER stress by salubrinal, an inhibitor of eIF2alpha dephosphorylation, abrogated SAHA's enhancement of CDDP cytotoxicity. Levels of phospho-Akt are decreased in SAHA-treated cells, and this is in turn associated with increased activity of protein phosphatase 1 (PP1) by SAHA, the phosphatase upstream of Akt.
CONCLUSION: These data indicate that up-regulation of specific-ER stress-associated events is an integral part of the mechanism by which SAHA enhances CDDP-induced apoptosis, and PP1 up-regulation followed by Akt dephosphorylation plays an important role in SAHA-enhanced CDDP apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19280190     DOI: 10.1007/s00280-009-0969-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Hdac3 is essential for the maintenance of chromatin structure and genome stability.

Authors:  Srividya Bhaskara; Sarah K Knutson; Guochun Jiang; Mahesh B Chandrasekharan; Andrew J Wilson; Siyuan Zheng; Ashwini Yenamandra; Kimberly Locke; Jia-Ling Yuan; Alyssa R Bonine-Summers; Christina E Wells; Jonathan F Kaiser; M Kay Washington; Zhongming Zhao; Florence F Wagner; Zu-Wen Sun; Fen Xia; Edward B Holson; Dineo Khabele; Scott W Hiebert
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

2.  Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.

Authors:  Ewelina Gumbarewicz; Jarogniew J Luszczki; Anna Wawruszak; Magdalena Dmoszynska-Graniczka; Aneta J Grabarska; Agata M Jarząb; Krzysztof Polberg; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

3.  A genome-wide RNA interference screen identifies caspase 4 as a factor required for tumor necrosis factor alpha signaling.

Authors:  Dorothee Nickles; Christina Falschlehner; Marie Metzig; Michael Boutros
Journal:  Mol Cell Biol       Date:  2012-06-25       Impact factor: 4.272

Review 4.  Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Emmanouil Kalampokas; Theodoros Kalampokas; Eleftherios Spartalis; Afrodite Daskalopoulou; Serena Valsami; Michael Kontos; Afroditi Nonni; Konstantinos Kontzoglou; Despina Perrea; Nikolaos Nikiteas; Dimitrios Dimitroulis
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

5.  Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells.

Authors:  Roberta Montalbano; Petra Waldegger; Karl Quint; Samir Jabari; Daniel Neureiter; Romana Illig; Matthias Ocker; Pietro Di Fazio
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

Review 6.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

7.  Between Scylla and Charibdis: eIF2α kinases as targets for cancer chemotherapy.

Authors:  Marta Moreno-Torres; José R Murguía
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

Review 8.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

9.  Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination.

Authors:  Carly St Germain; Anna O'Brien; Jim Dimitroulakos
Journal:  Cancer Cell Int       Date:  2010-09-09       Impact factor: 5.722

10.  Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Authors:  Katherine B Peters; Eric S Lipp; Elizabeth Miller; James E Herndon; Frances McSherry; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  J Neurooncol       Date:  2017-12-21       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.